Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

Author(s):

James K. McCloskey, MD, John Theurer Cancer Center,Thomas W. LeBlanc, MD, MA

Panelists discuss how they would initially assess and approach treatment for this patient case, considering their clinical experience and practice patterns in managing similar scenarios.

EP: 1.Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP: 2.Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP: 3.Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP: 4.Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP: 5.First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP: 6.Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP: 7.Second-Line LR- MDS Setting: Treatment Options and Considerations

Now Viewing

EP: 8.Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP: 9.Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP: 10.First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP: 11.Imetelstat and IMerge Trial Review

EP: 12.Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP: 13.The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

Please describe your initial impressions of this case. How might you have treated this patient in your practice.